Latest filingSep 11, 2026Most recent Form 4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/12 to 09/12. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$658M25 sells
Net open-market-$658M3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period27transactions
- S · Open-market sells · dominant25 · 93%
- A · Grants / awards2 · 7%
Activity by reported role
A joint filing can contribute to multiple roles27transactions
- PRES · dominant24 · 89%
- Director2 · 7%
- GC1 · 4%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeSibold William JohnCommon Stock · Direct
197,866Sep 11, 2026
Reed John CStock Option (Right to Buy) · Direct
1,078Aug 15, 2026
Reed John CCommon Stock · Direct
647Aug 15, 2026
Kelley Shannon TCommon Stock · Direct
11,474Aug 17, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 12 → Sep 12
LessMore
Top insiders
By absolute net value across the selected period- SJ-$6.2M
- KT-$341.9k
Recent filing activity
Most recent 12 transactions · color = transaction codeFiling detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
MDGL transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| MDGL | Sibold William John | PRES | sale10b5-1 | 120 | -$6.55M | S | — | 0.0% | 09/11 | 09/11 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 761 | -$41.4M | S | — | 0.0% | 09/11 | 09/11 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 1.53k | -$83.7M | S | — | 0.0% | 09/11 | 09/11 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 1.20k | -$65.2M | S | — | 0.0% | 09/11 | 09/11 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 368 | -$19.9M | S | — | 0.0% | 09/11 | 09/11 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 687 | -$37.1M | S | — | 0.0% | 09/11 | 09/11 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 160 | -$8.60M | S | — | 0.0% | 09/11 | 09/11 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 218 | -$11.6M | S | — | 0.0% | 09/11 | 09/11 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 106 | -$5.66M | S | — | 0.0% | 09/11 | 09/11 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 60 | -$3.19M | S | — | 0.0% | 09/11 | 09/11 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 160 | -$8.68M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 362 | -$19.6M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 505 | -$27.2M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 215 | -$11.5M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 520 | -$27.9M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 640 | -$34.3M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 1.04k | -$55.7M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 644 | -$34.4M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 396 | -$21.1M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 512 | -$27.2M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 368 | -$19.5M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 522 | -$27.6M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 347 | -$18.3M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Sibold William John | PRES | sale10b5-1 | 131 | -$6.91M | S | — | 0.0% | 09/11 | 09/09 |
| MDGL | Kelley Shannon T | GC | sale | 664 | -$34.1M | S | +3.8% | 08/20 | 08/17 |
MADRIGAL PHARMACEUTICALS, INC. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at MADRIGAL PHARMACEUTICALS, INC.?
Sibold William John, Kelley Shannon T, REED JOHN C.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Sibold William John reported a sale on Sep 11, 2026 valued at $6.55M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $6,581,138.22. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.